LONDON, Aug. 19 /PRNewswire/ -- Increasing knowledge related to the pathology of diabetes will support the introduction of improved drugs to treat the disease. As healthcare moves towards the ideal of preventive medicine, there are a few companies conducting research on diabetes vaccines. If they succeed, the entire market landscape is bound to undergo instant change.
New analysis from Frost & Sullivan (http://www.pharma.frost.com), Global Diabetes Market, finds that the market earned revenues of $27.00 billion in 2008 and estimates this to reach $44.70 billion in 2015.
If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Katja Feick, Corporate Communications, at firstname.lastname@example.org, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, a brief brochure will be sent to you by e-mail.
"Improved therapies and innovative drug delivery techniques are anticipated to revolutionise the global diabetes market by 2015," notes Frost & Sullivan Programme Leader Sylvia Miriyam Findlay. "As healthcare moves towards preventive medicine, the search for a cure for diabetes looks promising."
The emergence of newer classes of drug
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved